Noticias de CHRS_US

Noticias del mercado

Últimas noticias sobre CHRS_US — 32 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: CHRS_US ✕ 32 resultados
24/06/2026 CHRS_US — TradingKey ES ← EN
Coherus BioSciences Inc (CHRS) Salud financiera: análisis de rentabilidad y balance

Coherus BioSciences Inc (CHRS) Financial Health: Profitability & Balance Sheet Analysis

23/06/2026 CHRS_US — Investing.com
Coherus and Zumutor announce phase 1 cancer trial collaboration By Investing.com
18/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis
17/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings
17/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
17/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline
17/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Institutional Confidence
17/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates
17/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
17/06/2026 CHRS_US — TradingKey
Coherus BioSciences Inc (CHRS) Risk Assessment: Volatility, Financial Risk & Investment Risk
16/06/2026 CHRS_US — Investing.com ES ← EN
Coherus Oncology nombra a PwC nuevo auditor y sustituye a Ernst & Young Por Investing.com

Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young By Investing.com

15/06/2026 CHRS_US — Investing.com
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young
15/06/2026 CHRS_US — Investing.com
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young
01/06/2026 CHRS_US — Minichart
Coherus Oncology, Inc. 8-K SEC Filing: Company Details, Stock Information, and Compliance Disclosures (May 27, 2026)

Informe de la reunión anual de 2026 de Coherus Oncology, Inc.: aspectos destacados clave e impacto para los accionistas Reunión anual de accionistas de Coherus Oncology, Inc. 2026: resultados clave e impacto para los inversores Coherus Oncology, Inc. (NASDAQ: CHRS) celebró su Asamblea Anual de Accionistas de 2026 virtualmente el 27 de mayo de 2026, con un aplazamiento parcial hasta el 29 de mayo de 2026 para una propuesta específica. Este...

01/06/2026 CHRS_US — Investing.com ES ← EN
Los accionistas de Coherus Oncology aprueban la elección de directores y los cambios en el plan de acciones

Coherus Oncology shareholders approve director elections and equity plan changes

01/06/2026 CHRS_US — Investing.com ES ← EN
Los accionistas de Coherus Oncology aprueban la elección de directores y los cambios en el plan de acciones

Coherus Oncology shareholders approve director elections and equity plan changes

01/06/2026 CHRS_US — Investing.com ES ← EN
Los accionistas de Coherus Oncology aprueban la elección de directores y los cambios en el plan de acciones

Coherus Oncology shareholders approve director elections and equity plan changes

01/06/2026 CHRS_US — Investing.com Nigeria
Coherus Oncology shareholders approve director elections and equity plan changes
01/06/2026 CHRS_US — Investing.com South Africa
Coherus Oncology shareholders approve director elections and equity plan changes By Investing.com
01/06/2026 CHRS_US — Investing.com
Coherus Oncology shareholders approve director elections and equity plan changes

Página 1 de 2

keyboard_arrow_up